Tyrosine kinase inhibitor and rituximab-CHOP treatment for concurrent chronic myeloid leukemia and non-Hodgkin lymphoma: a case report.

Yuki TakeyasuAtsushi SatakeYoshiko AzumaYukie TsubokuraHideaki YoshimuraMasaaki HottaTakahisa NakanishiShinya FujitaAya NakayaTomoki ItoShosaku Nomura

Published in: Clinical case reports (2017)

Non-Hodgkin lymphoma can occur concurrently with chronic phase-chronic myeloid leukemia (CML) at initial diagnosis. Combination treatment with second-generation tyrosine kinase inhibitors and rituximab-CHOP for patients newly diagnosed with CML and non-Hodgkin lymphoma is effective for both diseases. However, we found that this treatment combination may induce severe myelosuppression.

Keyphrases

chronic myeloid leukemia
newly diagnosed
diffuse large b cell lymphoma
end stage renal disease
chronic kidney disease
early onset
combination therapy
replacement therapy